Int'l : +1(646) 600-5072 | query@kbvresearch.com
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Europe Autoimmune Disease Therapeutics Market, published by KBV research, the Europe Autoimmune Disease Therapeutics Market would witness market growth of 3.94% CAGR during the forecast period (2019-2025).
The Germany market dominated the Europe Inflammatory Bowel Disease Market by Country in 2018, growing at a CAGR of 3.5 % during the forecast period. The UK market is expected to witness a CAGR of 3.2% during (2019-2025). Additionally, The France market is expected to witness a CAGR of 5.5% during (2019-2025).
The Anti-Inflammatory market dominated the Europe Autoimmune Disease Therapeutics Market by Drug Class in 2018, growing at a CAGR of 4.1 % during the forecast period. The Anti-Hyperglycemics market is expected to witness a CAGR of 4.3% during (2019-2025).
The Retail Pharmacies and Drug Stores market dominated the France Autoimmune Disease Therapeutics Market by Distribution Channel in 2018, thereby, achieving a market value of $3,555.4 million by 2025, growing at a CAGR of 5.1 % during the forecast period. The Online market is expected to witness a CAGR of 5.5% during (2019-2025).
Full Report: https://www.kbvresearch.com/europe-autoimmune-disease-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis AG.
By Indication
By Drug Class
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from KBV Research